Crinetics stock price target raised to $87 from $73 at Oppenheimer

Crinetics Pharmaceuticals (NASDAQ:CRNX) shares surged over 21% following FDA approval of its acromegaly treatment, Palsonify, prompting multiple research firms including Oppenheimer, Stifel, and Morgan Stanley to significantly raise their price targets. Analysts cited Palsonify's higher-than-expected annual list price of $290,000 and broad label as key drivers, with Oppenheimer now projecting global sales to reach $419 million by 2028, substantially exceeding consensus estimates. This strong outlook, coupled with the company's robust financial position and pipeline, suggests Crinetics shares are currently considered "considerably undervalued" by some analysts.

Analysis

Crinetics Pharmaceuticals (CRNX) has received a significant positive re-rating following the FDA's approval of its acromegaly treatment, Palsonify. This regulatory milestone catalyzed a stock surge of over 21% in the past week and prompted a wave of bullish analyst revisions. Oppenheimer raised its price target to $87 from $73, underpinned by revised sales forecasts for Palsonify that substantially exceed consensus: their projection of $419 million in 2028 sales is 40% higher than the Visible Alpha consensus of $300 million. The positive sentiment is driven by two key factors: a higher-than-expected annual list price of $290,000 and a broad label that expands the drug's market potential. Other firms, including Stifel, Piper Sandler, and Morgan Stanley, have issued similar price target increases, creating a strong institutional consensus. Oppenheimer's valuation framework suggests the market is underappreciating the company's potential, assigning approximately $45 per share to the acromegaly opportunity and future cash reserves alone, thereby treating the earlier-stage pipeline as a source of further, unpriced upside. This thesis is supported by the company's robust financial health, evidenced by a current ratio of 17.8x and a balance sheet with more cash than debt, which mitigates financing risk during the critical commercial launch phase.

Key Decisions for Investors

• Investors should consider that current consensus estimates for Palsonify may be too conservative, presenting an opportunity if the company executes on more bullish analyst projections like Oppenheimer's.
• The key risk has shifted from regulatory approval to commercial execution; monitor early prescription trends and payer negotiations, as the high $290,000 list price could face market access challenges.
• Given that some valuation models suggest the current share price is largely supported by Palsonify and cash, the company's earlier-stage pipeline, including atumelnant, represents a potential source of significant future upside not fully priced in.